Welcome to our dedicated page for Contineum Therapeutics SEC filings (Ticker: CTNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Contineum Therapeutics, Inc. (CTNM) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a Nasdaq-listed clinical-stage biopharmaceutical issuer. Contineum files current reports on Form 8-K to describe material events such as clinical data readouts, financing transactions, shareholder votes and trial design updates, alongside its other periodic SEC reports.
For CTNM, clinical development milestones are a recurring theme in its filings. Form 8-K reports have summarized topline data from the PIPE-307 Phase 2 VISTA trial in relapsing-remitting multiple sclerosis and positive topline data from the PIPE-791 Phase 1b PET trial assessing LPA1 receptor occupancy in healthy volunteers and progressive multiple sclerosis patients. Another 8-K details the design of a 26-week, international, randomized, double-blind, placebo-controlled Phase 2 trial of PIPE-791 in idiopathic pulmonary fibrosis, including its primary efficacy measure based on change in forced vital capacity.
Filings also document capital markets activity. Contineum has reported entering into an underwriting agreement for an upsized public offering of its Class A common stock under a shelf registration statement on Form S-3, as well as prior at-the-market offerings. These disclosures outline the terms of offerings, estimated net proceeds and related exhibits such as underwriting agreements and legal opinions.
Investors can use this page to review CTNM’s governance and shareholder matters, including results of its annual meeting of stockholders reported on Form 8-K, where director elections and auditor ratification votes are recorded. With real-time updates from EDGAR and AI-powered summaries, this filings page helps readers quickly understand the key points in Contineum’s 8-Ks and related exhibits, while still allowing full-text access to the underlying SEC documents for deeper analysis.
Contineum Therapeutics, Inc. furnished an 8-K to announce it issued a press release with financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The information under Item 2.02, including Exhibit 99.1, is being furnished and is not deemed “filed” for purposes of Section 18 of the Exchange Act, and will not be incorporated by reference into any Securities Act registration statement unless specifically identified.
Contineum Therapeutics reported that a pharmacokinetic–pharmacodynamic relationship between exposure to its investigational drug PIPE-791 and LPA1 brain receptor occupancy (RO) was confirmed in both healthy volunteers and progressive multiple sclerosis (PrMS) patients. Plasma EC50 values were 37 ng/mL at 24 hours and 12 ng/mL at 168 hours post-dose, indicating sustained target engagement after dosing. The company states its planned Phase 2 proof-of-concept doses are expected to provide >90% target coverage at trough with once-daily dosing.
The filing also contains customary forward-looking statements and risk disclosures noting that these early clinical results may not predict future outcomes and that development, regulatory, and funding risks could affect plans.
Contineum Therapeutics, Inc. Schedule 13G/A filed by Perceptive Advisors LLC, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. reports that the Master Fund directly holds 699,486 shares of Class A common stock, representing 3.2% of the outstanding class based on 21,625,223 shares. Perceptive Advisors, as investment manager, and Mr. Edelman, as managing member, each disclose the same beneficial ownership because they may be deemed to beneficially own the Master Fund's position. The filing shows no sole voting or dispositive power and only shared voting and dispositive power for the reported shares. The filing states the position was not acquired to influence control of the issuer.
Franklin Resources, Inc., its subsidiary Franklin Advisers, Inc., and related control persons filed Amendment No. 1 to Schedule 13G for Contineum Therapeutics, Inc. (CTNM) covering Class A common stock (CUSIP 21217B100) as of 30 June 2025.
- Shares owned: 1,698,825.
- Percent of outstanding class: 8.9%.
- Voting & dispositive power: Sole power resides with Franklin Advisers; no shared power reported.
- Individuals Charles B. Johnson and Rupert H. Johnson, Jr. report 0 shares.
- The largest underlying account, Franklin Biotechnology Discovery Fund, holds 1,100,717 shares (5.8%).
- Filers certify the stake is held in the ordinary course of business with no intent to influence control.
No financial results, transactions, or additional corporate events are disclosed in this filing.
Form 4 Overview: On 06/26/2025, Contineum Therapeutics (CTNM) filed a Form 4 reporting that non-employee director Sarah Boyce received a stock option grant for 14,750 shares of the company’s Class A common stock at an exercise price of $4.01 per share. The option was issued under the company’s 2024 Equity Incentive Plan as part of the regular non-employee director compensation program.
Key Terms: The option vests in full on the earlier of (i) June 26, 2026 (one-year anniversary of the grant) or (ii) the next regular annual meeting of stockholders, provided Ms. Boyce remains a board member. It expires on 06/25/2035.
Post-Transaction Holdings: Following this transaction, Ms. Boyce beneficially owns 14,750 derivative securities (stock options) directly.
Investor Takeaway: The filing reflects routine director compensation and signals alignment of director incentives with shareholder value; financial impact and dilution are immaterial relative to typical public company share counts.
Contineum Therapeutics, Inc. (CTNM) – Form 4 insider filing
On 26 June 2025, non-employee director Evert B. Schimmelpennink received a routine annual stock-option grant under the company’s 2024 Equity Incentive Plan. The award covers 14,750 shares of Class A Common Stock with an exercise price of $4.01 and expires on 25 June 2035. The option vests in full on the earlier of 26 June 2026 or the next regular annual shareholder meeting, contingent upon continuous board service.
The filing reports no open-market purchase or sale of shares; it solely reflects a compensatory grant made pursuant to the Board’s non-employee director compensation program. Following the grant, the director beneficially owns 14,750 derivative securities directly. No other transactions or changes in ownership were disclosed.
Because the transaction is part of a pre-established compensation policy and involves a small percentage of outstanding shares, it is unlikely to have a material impact on the company’s capital structure or near-term valuation.
Contineum Therapeutics, Inc. (CTNM) – Form 4 insider transaction filed 06/26/2025
Director Todd R. Brady reported the grant of a non-qualified stock option covering 14,750 shares of the company’s Class A common stock at an exercise price of $4.01 per share. The option was issued under the company’s 2024 Equity Incentive Plan as part of the regular Non-Employee Director Compensation Program.
Key terms
- Grant date: 26 Jun 2025
- Vesting: 100 % on the earlier of 26 Jun 2026 (one-year anniversary) or the next annual stockholders’ meeting, contingent on continuous board service
- Expiration: 25 Jun 2035 (10-year term)
- Form of ownership: Direct
- No open-market purchases or sales of common shares were reported in Table I
The filing increases Brady’s reported derivative holdings to 14,750 options; no changes were disclosed for non-derivative share ownership. The transaction is routine board compensation and does not affect the company’s share count, cash position, or operating fundamentals. Investors should view it primarily as a standard alignment mechanism between the director and shareholders rather than a catalyst for valuation change.
Contineum Therapeutics, Inc. (CTNM) – Form 4 Insider Filing
On 26 June 2025, non-employee director Troy A. Ignelzi reported the grant of 14,750 stock options under the company’s 2024 Equity Incentive Plan and Non-Employee Director Compensation Program. The options carry an exercise price of $4.01 per share, expire on 25 June 2035, and will vest in full on the earlier of 26 June 2026 (one-year anniversary) or the next annual shareholders’ meeting, subject to continued board service.
The filing shows no disposition of shares; it solely reflects an automatic annual equity grant to a board member. Following the grant, Ignelzi beneficially owns 14,750 derivative securities (options) and no change in direct common-stock ownership was reported.
Because this is a routine director compensation grant rather than an open-market purchase or sale, the event is generally viewed as neutral from a market-moving perspective.